FDA Approves Opioid Overdose Reversal Injection for Ages 12+ Amid Rising Teen Deaths

The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

To combat the ongoing opioid crisis in the United States, the U.S. Food and Drug Administration (FDA) has approved Zurnai, the first nalmefene hydrochloride auto-injector for emergency treatment of known or suspected synthetic opioid overdoses in adults and pediatric patients aged 12 years and older.

The approval brings the addition of another tool in the FDA’s toolbox and plan to broaden access to overdose reversal agents, including naloxone and nalmefene.